In particular, TGF-β inhibitors are being evaluated in combination with PD-L1 antibodies in trials for metastatic triple-negative breast cancer, with the aim of converting immunologically inactive tumors into responsive ones. This evidence concerns the gene TGFB1 and triple-negative breast carcinoma.